231 results about "In vivo tests" patented technology

High purity water, particularly that intended for the pharmaceutical or electronics industry, is analyzed for the presence of pyrogen or other impurities by causing the water to come into contact with a direct affinity sensor, which may be a surface plasmon resonance (SPR) device or other sensor relying on an evanescent wave phenomenon. A property of the surface-refractive index in the case of SPR-changes on the binding of impurity, thereby enabling impurity to be detected. The invention overcomes the cumbersome nature and batch-to-batch variability of the conventional in vivo tests as well as the in vitro Limulus Amoebocyte Lysate (LAL) assay and for the first time allows the continuous or real time monitoring of high purity water for pyrogen.

A Lactobacillus plantarum BB9 capable of adhering to gastrointestinal tract and cholesterol removal is isolated from fruits and exhibits high BSH activity. In-vitro tests demonstrate that Lactobacillus plantarum BB9 has good acid and bile tolerance, and strong ability to adhere to intestinal cells. In-vivo tests show that hamsters fed high cholesterol diets added with BB9 strain have cholesterol and triglycerides in blood and liver effectively reduced, and their HDL-c/LDL-c ratios in blood are significantly higher than those of hamsters fed Lactobacillus acidophilus ATCC 43121 strain. It is hoped that the excellent acid and bile tolerance and intestinal adherence of the lactobacillus strain provided herein could produce cholesterol-lowering effect in humans.

This patent describes a novel in vitro cell-based method for biological validation and pharmacological screening of drugs, new chemical entities (NCEs) and biologics, which is predictive of in vivo testing for efficacy and adverse events in patients, as occurs in clinical trials. The same method can be used to create an in vitro cell-based assay to identify the ‘right marketed medication for the right patient’ (personalized medicine), and to identify responders/non-responders in ongoing clinical trials with NCEs. In addition this approach can be used to identify new indications for existing medicines and new indications for NCEs that were unsuccessful in their intended uses.

The invention discloses application of A-nor-5 alpha-androstane compounds in preparation of malignant tumor resistant medicaments. The compounds have the following general formula I, and comprise Ia, Ib, Ic, Id, Ie and If. The growth inhibition rate of the A-nor-5 alpha-androstane compounds for in-vitro human liver cancer cell Hep 3B, human breast cancer MDA-MB-231, human lung adenocarcinoma A549 and mouse melanoma B16 is higher than 85% on average, and even up to 99.98% to the maximum. The in-vivo test proves that the inhibition rate of the A-nor-5 alpha-androstane compounds for mouse tumors, such as intestinal cancer C26, liver cancer H22, Lewis lung cancer, breast cancer, B16 melanoma and the like, is higher than 50% on average, and even up to 63.19% to the maximum. The result proves that the compounds disclosed by the invention have an obvious malignant tumor resistant action. The A-nor-5 alpha-androstane compounds disclosed by the invention have an obvious and broad-spectrum action on inhibiting growth of malignant tumor cells, and are novel targeted malignant tumor resistant medicaments with low drug toxicity and favorable treatment effect; and the A-nor-5 alpha-androstane compounds just specifically act on tumor cells, but not influence normal cells, thereby having a high clinical application value.

The present invention relates to probiotic microorganisms producing chimeric human growth hormone for oral use and methods for preparing them.

The invention provides probiotic Lactobacillus or yeast transformant expressing chimeric protein which is human growth hormone fused with Fc fragment of human IgG, in which the transformants are safely delivered into intestine though oral route. Also, the invention provides a chimeric protein-expressing vector which can induce transcytosis in intestine epithelial cells.

Accordingly, the invention demonstrates that the chimeric protein for oral delivery system can be absorbed in intestine, and delivery of the chimeric protein by oral route using Lactobacillus has very excellent efficiency in vivo test in rats. Accordingly, the Lactobacillus of the present invention is an excellent deliverer of protein drugs.

In vivo testing for analytes in a life-form is an attractive concept because a biological sample does not have to be removed from the life-form. However, in vivo testing alone is unable to provide information that is accurate, complete and/or reliable enough to safely replace in vitro testing. In contrast to performing either in vivo or in vitro testing independently and alone, some embodiments of the present invention provide a joint-diagnostic apparatus for combined in vivo and in vitro testing. In some specific embodiments results from an in vitro measurement module are used in combination with subsequent in vivo measurements/observations obtained at a later time, and/or vice versa. Accordingly, in some embodiments in vitro measurements are used to compliment and/or partially compensate for some of the limitations of in vivo testing, and at the same time enabling some of the benefits of in vivo testing by reducing the number of biological samples taken.

The present invention provides a method for identifying a compound or a combination of compounds having a pharmacological behavior that qualifies it as a candidate for clinical development of a drug for treatment of a psychiatric disease or disorder, preferably schizophrenia. According to this method, a candidate drug is assessed for its ability to produce a biochemical profile, in either or both in vitro and in vivo test systems, which is similar to a unique reference biochemical profile obtained following treatments with drugs or drug combinations effective against both positive and negative symptoms of psychiatric diseases or disorders.

Formulations and methods for preventing, inhibiting or controlling metabolic disorder, age-related disease and acute inflammations have been developed. The compositions comprise of bilirubins, bilirubin derivatives, their tetrapyrrolic analogues, tripyrroles, and dipyrroles. The compositions can be administered as a dosage form for oral ingestion, injection, suppository, or topical application. The effective amount of the compound is typically from 0.001-100 mg/kg body weight, preferably in the range from 0.01-50 mg/kg body weight, and most preferably from 0.05-10 mg/kg body weight. Examples demonstrate the efficacy of the compounds in both in vitro and in vivo tests.

The invention belongs to the technical field of biological products and discloses a medicinal composition and application thereof. The composition takes recombinant human endostatin and hexadecadrol as effective constituents, wherein the mole ratio of the recombinant human endostatin to the hexadecadrol is 10-100:1. The recombinant human endostatin in the combination can co-act with the hexadecadrol to restrain the multiplication, invasion, migration and angiogenesis of endothelial cells. An in-vivo test result proves that the recombinant human endostatin and the hexadecadrol co-act with each other to restrain the growth of the mice H22 transplanted liver tumor and human Bel7402 transplanted liver tumor. Therefore, the composition can be widely applied to medicaments for treating liver cancer.

The invention discloses a nucleotide sequence and an amino acid sequence of a human derived membrane-stabilization mutant gene CD40L-M, and a plasmid carrier pdsAAV-CB-CD40L-M. The invention further discloses a recombinant adeno-associated virus scAAV2/5-Y719F-CD40L-M using CD40L-M as a target gene and highly-efficiently transducing lung cancer cells, a preparation method thereof, and an application thereof in preparing anti-cancer drugs. In vitro and in vivo tests of transduction of the CD40L-M gene into the lung cancer cells show that generation of the sCD40L is substantially reduced, a traditional AAV transduction efficiency is improved by using the recombinant adeno-associated virus scAAV2/5-Y719F-CD40L-M, the lung cancer cells can be highly-efficiently transduced, and the CD40L-M gene induces retardance of cell cycles, promotes cell apoptosis, induces immunization activation, inhibits growth of lung cancer in the body and reduces side effects such as liver and kidney damage.

The invention relates to a bispecific oligopeptide-lidamycin energized fusion protein Ec-LDP-Hr-AE. The fusion protein comprises two oligopeptides of targeted epidermal growth factor receptors EGFR and HER2, a lidamycin apoprotein and a lidamycin activity chromophore, and researches show that the fusion protein in vitro can be combined with the epidermal growth factor receptors EGFR and HER2 for expressing the specificities of the tumor cells, has strong damaging effect for the tumor cells and remarkable therapeutic effect for the transplanted tumor of nude mice for the ovarian cancer SK-OV-3 after the in vivo test, displays the characteristics of miniaturization and high efficiency of targeting drugs and has good application prospect.

The genome of the non-human mutant mammal, deficient in an endogenous Sigma receptor, contains a mutation that comprises a disruption in an endogenous Sigma rteceptor gene, wherein said gene disruption gives rise to a mutant lacking detectable levels of endogenous Sigma receptor. The mutant may be used as a control animal for in vivo tests, as well as a source of cells that can be used in in vitro tests, Mutants deficient in the Sigma-1 receptor can be used as models for in vivo study of disorders of the central nervous system, memory alterations, stress conditions and drug addictions, analgesia processes and neuroprotection. Mutants deficient in the Sigma-2 receptor can be used to study diagnostic or therapeutic tools to fight cance and/or degenerative processes and/or to design compounds capable of preventing, reducing or alleviating the secondary pathology associated with administration of neuroleptic agents.

The invention discloses Lactobacillus fermentum zhao capable of regulating intestinal movement and preventing constipation and application thereof, wherein the preservation number of the Lactobacillus fermentum zhao is CCTCCM2013513. The strain has higher acid resistance, has a survival rate reaching 85.12% plus/minus 5.18% after staying in pH3.0 artificial gastric juice for 3 h, can grow slowly in cholate with the concentration of 1.0% and has a growth efficiency reaching 18.33% plus/minus 0.52% of that of cholate-free culture. The hydrophobicity of Lactobacillus fermentum zhao cells is up to 70.80% plus/minus 0.61%. The Lactobacillus fermentum zhao can grow normally in human intestinal tracts. In-vivo tests using mice show that the Lactobacillus fermentum zhao can reduce the weight reduction tendency of the mice, shorten the time of defecation of dark stool, improve the peristalsis of small intestines, increase MTL, Gas, ET, AchE, SP and VIP factors to different extents, reduce SS factors, increase food consumption and water consumption, reduce the tendency that stool amount, stool pieces and stool water content decline, play an effect similar to that of a constipation medicine and show a certain constipation prevention effect.

The invention relates to a fluorescent probe capable of reversibly detecting a hypoxic environment and used in a living body environment. The fluorescent probe adopts a quinone functional group capable of performing reversible oxidation-reduction reaction in the vivo biological environment as a receptor, and uses a fluorophore of which the wave length is in a near infrared band as a signal source, and the receptor and the signal source are connected through an applicable connecting arm. In-vitro and in-vivo tests show that the probe can realize free conversion under aerobic and hypoxic conditions, and can be used in tracking of a hypoxic zone in vivo; under the hypoxic condition, fluorescent emitted by the fluorescent probe excited by laser with the wave length of 680 nm can be obviously found at a point of which the wave length is 790 nm; while under the aerobic microenvironment, the fluorescent completely disappears, so that transfer of the hypoxic zone in a body of a tumor patient can be tracked, thereby providing a judgment basis for clinical individualized administration.

A composition contains an extract of pine leaf extract or a compound isolated therefrom. It showed potent inhibitory effect on human papillomavirus (HPV) as well as anti-cancer effect on various cancer diseases through various in vitro test and in vivo tests, and therefore, it can be used as the effective and safe therapeutics or health food for treating and preventing cancer disease.

The invention relates to application of natural compound ursolic acid on antibiosis, in particular to application of the combination of the natural compound ursolic acid and penicillin on resisting drug resistant staphylococcus aureus. The compound ursolic acid is widely distributed in nature, so that the material source is wide. Aiming at the serious problem of the drug resistance of the staphylococcus aureus at present, the in vitro and in vivo antibiotic tests are carried out for the ursolic acid. Particularly the in vitro synergic test proves that the ursolic acid has better antibacterial activity on the drug resistant staphylococcus aureus under the combination action of the ursolic acid and the penicillin, and the lowest bacteriostatic concentration is 1.13 mu g/disc; moreover, the in vivo test also shows that the ursolic acid has better activity under the synergic action.

The invention discloses HLA-A2 restrictive epitope polypeptide of an LMP2A protein source, which is polypeptide LMP2A264 and comprises 9 amino acids in the positions of 264 to 272; the sequence is QLSPLLGAV. Mycobacteria heat shock protein 70 (HSP70) is expressed, identified and purified; a transgene animal model for evaluating EBV relevant polypeptide vaccine in vivo tests is established; the immune research on inducing EBV specific CTL inside and outside healthy volunteers and transgene rats for the new EBV epitope polypeptide LMP2A264 is systemically researched and the tumor prevention andthe tumor treating test of the polypeptide LMP2A264 on LMP2A positive solid tumors are evaluated, thereby proving that the polypeptide LMP2A264 can induce LMP2A specific cell toxic T lymphocyte reaction. Therefore, the polypeptide LMP2A264 can be applied to prepare medicaments for treating or preventing LMP2A positive solid tumors.

The invention discloses a series of urea transporter inhibitors of which the structural formula is disclosed in the specification. An erythrocyte model is used for screening to obtain compounds for inhibiting urea transporters. The experimental result indicates that the compounds (such as Youti) can inhibit the permeation of urea transporter UT-B mediated erythrocyte membranes for urea, and the action forms a dosage dependency relationship; Youti within effective dose range has no cytotoxic action on the MDCK (Madin-Darby Canine Kidney) cells, which indicates that the action of Youti for inhibiting cell permeable urea is irrelevant to cytotoxicity; the inhibiting action of Youti on the urea transporter UT-B gradually increases; the inhibiting action of Youti on the urea transporter UT-B is reversible; and the in-vivo test result proves that Youti can obviously increase the uresis amount of a rat, lower the concentration of urea in the urine of the rat, and lower the osmotic pressure, which indicates that Youti has selective diuresis action on urea in vivo.

The invention discloses an application of alpha-mangostin in controlling plant diseases. Tests prove that alpha-mangostin has agricultural fungicidal activity. The compound has very strong fungistatic action on mango anthracnose pathogens, diplodina sp., botrytis cinerea, and exserohilum turcicum when the testing concentration is 100 mg/L, and has an EC50 value of 18 mg/L-35 mg/L; the compound has certain spore germination inhibition effect on exserohilum turcicum and botrytis cinerea, and the EC50 values are 66.20 mg/L and 50.43 mg/L respectively; meanwhile, in-vivo test results show that the compound has very good protection and treatment effects on rubber tree powdery mildew when the testing concentration is 500 mg/L, and the protection and treatment effects on rubber tree powdery mildew are 75.61% and 70.12% respectively, which are higher than those of a control drug of prochloraz. The above results indicate that alpha-mangostin has broad-spectrum fungistatic action on plant pathogenic fungi, which lays the foundation for the development of novel pollution-free plant-derived pesticides by further using mangosteen shells.